A Phase 3b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Effect of Dalcetrapib 600 mg on Cardiovascular (CV) Events in Adult Patients With Stable Coronary Heart Disease (CHD), CHD Risk Equivalents or at Elevated Risk for Cardiovascular Disease (CVD)

Trial Profile

A Phase 3b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Effect of Dalcetrapib 600 mg on Cardiovascular (CV) Events in Adult Patients With Stable Coronary Heart Disease (CHD), CHD Risk Equivalents or at Elevated Risk for Cardiovascular Disease (CVD)

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Sep 2016

At a glance

  • Drugs Dalcetrapib (Primary)
  • Indications Cardiovascular disorders; Coronary artery disease; Dyslipidaemias; Peripheral arterial disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms dal-OUTCOMES 2
  • Sponsors Roche
  • Most Recent Events

    • 01 Nov 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Aug 2012 Status changed from discontinued to recruiting as reported by ClinicalTrials.gov.
    • 07 May 2012 Status changed from recruiting to discontinued as reported by Roche.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top